StockData
MASSNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

908 Devices Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$11.43+0.17 (+1.51%)

Close on Oct 19, 2026

Market cap
$431.23M
P/E (TTM)
–
Dividend yield
–

About 908 Devices

Laboratory Analytical Instruments, SIC 3826

908 Devices develops and manufactures portable devices for chemical analysis at the point of need using mass spectrometry and optical spectroscopy technologies. Its portfolio includes handheld instruments such as the MX908, ThreatID, ProtectIR, XplorIR, and VipIR, alongside sampling consumables, extended warranty plans, on-site training, and round-the-clock technical support. The business serves government and life sciences markets, providing measurement tools to civilian first responders, military personnel, hazmat teams, customs and border agents, and law enforcement officers.

The company has deployed more than 3,700 devices across all fifty U.S. states and five continents to over 700 customer accounts. Commercial reach includes a direct North American sales organization and more than 64 domestic and international distribution partners. Primary manufacturing takes place in Danbury, Connecticut, supported by machining sites in Stamford, Connecticut, and Georgetown, Massachusetts, as well as research facilities in Burlington, Massachusetts, and Danbury. The text does not specify a corporate headquarters location.

Summary of the business section of 908 Devices's latest annual report, written by StockData.

Company profile

Company

Legal name
908 Devices Inc.
Headquarters
Burlington, MA
Address
44 Third Avenue 01803
Phone
(978) 729-4478
Employees
172, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers, LLP, Boston, Massachusetts

Stock & identifiers

Ticker
MASS
Exchange
Nasdaq
IPO date
Dec 18, 2020
Shares outstanding
41M, Aug 7, 2026
Public float
$194.90M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1555279
CUSIP
65443P102
ISIN
US65443P1021
EIN
45-4524096

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Kevin J. KnoppPresident and CEO, Director1,097,191
John KennewegSVP, Sales & Product Marketing57,784
Joseph H. Griffith IVChief Financial Officer121,497
Kolawole A. OtitojuChief Bus. & Strategy Officer–
Kevin J. McCallionSVP, Products and Production44,925
Mark S. LevineChief Legal and Admin. Officer–
Michael S. TurnerChief Legal & Admin Officer0
Christopher D. BrownDirector775,559
Brandi C. VannDirector5,192
Michele M. LeonhartDirector27,054
Anthony HuntDirector44,168
E. Kevin HrusovskyDirector495,065
Mark SpotoDirector92,945
Fenel M. EloiDirector40,897
Keith CrandellDirector5,764,419
Jeffrey P. GeorgeDirector26,814
Marcia EisenbergDirector25,957

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Kevin J. Knopp, Ph.D. was our PEO for bothyears presented.
$1.55M$3.05M$1.24M$47–
FY2024
Kevin J. Knopp, Ph.D. was our PEO for bothyears presented.
$1.99M$29.39K$1.22M$20–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 172 full-time employees, of which 35 work in sales, sales support and marketing, 43 work in engineering and research and development, 62 work in manufacturing, operations and service and 32 work in general and administrative.”

Corporate history

Events identified from SEC filings